systematic_review
    2011

    Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence

    Iavazzo C, Gkegkes ID, Zarkada IM

    Published in Journal of Women's Health

    Methodology

    Systematic review of 14 studies of intravaginal boric acid for recurrent and azole-resistant vulvovaginal candidiasis.

    Key Findings

    Boric acid achieved mycological cure rates of 40-100%, with particular value in non-albicans and azole-resistant species.

    Conclusions

    Boric acid is a reasonable second-line option for resistant recurrent candidiasis under clinical supervision.

    Limitations

    Mostly uncontrolled series; toxicity if taken orally; not for pregnancy.

    Related Health Concerns

    Candida Overgrowth

    Study Details

    Year:2011
    Sample Size:141
    Quality Score:6/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.